Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Vildagliptin 50 mg bid
Vildagliptin 50 mg qd
Placebo
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes Mellitus, HbA1c reduction, vildagliptin, add-on to metformin, Chinese patients
Eligibility Criteria
Inclusion Criteria:
- Patients with T2DM who have received metformin for at least 8 weeks and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1
- Agreement to maintain the same dose of metformin from randomization to the end of the study
- Age in the range of 18-78 years inclusive
- Body mass index (BMI) in the range of 20-40 kg/m2 inclusive at Visit 1
- HbA1c in the range of > 7.0 to ≤10% at Visit 1
- Agreement to maintain prior diet and exercise habits during the full course of the study
- Ability to comply with all study requirements
Exclusion Criteria:
- Fasting Plasma Glucose (FPG) > 270 mg/dl (15 mmol/L) at Visit 1
- Pregnant or nursing (lactating) women
Other protocol-defined inclusion/exclusion criteria may apply
Sites / Locations
- China-Japan Friendship Hospital
- General Hospital of Beijing Military Region of PLA
- Peking Union Medical College Hospital
- Peking University First Hospital
- The General Hospital of the PLA
- The General Hospital of the Second Artilleryman of PLA
- The Affiliated Union Hospital of Fujian Medical University
- The Fuzhou General Hospital of the PLA Nanjing Military Area
- Guangdong Provincial People's Hospital
- Second Affiliated Hospital of Nanchang University
- The Jiangxi Provincial People's Hospital
- Te Affiliated Drum Tower of Nanjing University Medical School
- Tongji Hospital of Tongji University
- Shanghai Changzheng Hospital
- The Second Affiliated Hospital of China Medical University
- The Second Affiliated Hospital of Tianjin Medical University
- First Affiliated Hospital of 4th Military Medical University
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Placebo Comparator
Arm Label
Vildagliptin Dose 1
Vildagliptin Dose 2
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Change from baseline in HbA1c after 24 weeks
Secondary Outcome Measures
Percent of patients with HbA1c < 7% after 24 weeks
Adverse event profile after 24 weeks of treatment
Change from baseline in fasting plasma glucose at 24 weeks
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00822211
Brief Title
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
Official Title
A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Effect of 24 Weeks Treatment With Vildagliptin 50 mg Bid to Placebo as Add-On Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
Study Type
Interventional
2. Study Status
Record Verification Date
November 2016
Overall Recruitment Status
Completed
Study Start Date
December 2008 (undefined)
Primary Completion Date
December 2009 (Actual)
Study Completion Date
December 2009 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to assess the efficacy and safety of vildagliptin 50 mg bid compared to placebo as an add-on therapy to metformin in Chinese patients with T2DM inadequately controlled by metformin alone.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Diabetes Mellitus, HbA1c reduction, vildagliptin, add-on to metformin, Chinese patients
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
404 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Vildagliptin Dose 1
Arm Type
Experimental
Arm Title
Vildagliptin Dose 2
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Drug
Intervention Name(s)
Vildagliptin 50 mg bid
Intervention Type
Drug
Intervention Name(s)
Vildagliptin 50 mg qd
Intervention Type
Drug
Intervention Name(s)
Placebo
Primary Outcome Measure Information:
Title
Change from baseline in HbA1c after 24 weeks
Time Frame
24 weeks
Secondary Outcome Measure Information:
Title
Percent of patients with HbA1c < 7% after 24 weeks
Time Frame
24 weeks
Title
Adverse event profile after 24 weeks of treatment
Time Frame
24 weeks
Title
Change from baseline in fasting plasma glucose at 24 weeks
Time Frame
24 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
78 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with T2DM who have received metformin for at least 8 weeks and have been on a stable dose of at least 1500 mg daily for a minimum of 4 weeks prior to visit 1
Agreement to maintain the same dose of metformin from randomization to the end of the study
Age in the range of 18-78 years inclusive
Body mass index (BMI) in the range of 20-40 kg/m2 inclusive at Visit 1
HbA1c in the range of > 7.0 to ≤10% at Visit 1
Agreement to maintain prior diet and exercise habits during the full course of the study
Ability to comply with all study requirements
Exclusion Criteria:
Fasting Plasma Glucose (FPG) > 270 mg/dl (15 mmol/L) at Visit 1
Pregnant or nursing (lactating) women
Other protocol-defined inclusion/exclusion criteria may apply
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Director
Facility Information:
Facility Name
China-Japan Friendship Hospital
City
Beijing
Country
China
Facility Name
General Hospital of Beijing Military Region of PLA
City
Beijing
Country
China
Facility Name
Peking Union Medical College Hospital
City
Beijing
Country
China
Facility Name
Peking University First Hospital
City
Beijing
Country
China
Facility Name
The General Hospital of the PLA
City
Beijing
Country
China
Facility Name
The General Hospital of the Second Artilleryman of PLA
City
Beijing
Country
China
Facility Name
The Affiliated Union Hospital of Fujian Medical University
City
Fuzhou
Country
China
Facility Name
The Fuzhou General Hospital of the PLA Nanjing Military Area
City
Fuzhou
Country
China
Facility Name
Guangdong Provincial People's Hospital
City
Guangzhou
Country
China
Facility Name
Second Affiliated Hospital of Nanchang University
City
Nanchang
Country
China
Facility Name
The Jiangxi Provincial People's Hospital
City
Nanchang
Country
China
Facility Name
Te Affiliated Drum Tower of Nanjing University Medical School
City
Nanjing
Country
China
Facility Name
Tongji Hospital of Tongji University
City
Nanjing
Country
China
Facility Name
Shanghai Changzheng Hospital
City
Shanghai
Country
China
Facility Name
The Second Affiliated Hospital of China Medical University
City
Shenyang
Country
China
Facility Name
The Second Affiliated Hospital of Tianjin Medical University
City
Tianjin
Country
China
Facility Name
First Affiliated Hospital of 4th Military Medical University
City
Xi'an
Country
China
12. IPD Sharing Statement
Citations:
PubMed Identifier
22369287
Citation
Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, Lv X, Lu J, Bader G; Institution Investigators. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Aug;14(8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x. Epub 2012 Apr 1.
Results Reference
result
Learn more about this trial
Efficacy of add-on Therapy With Vildagliptin in Chinese Patients With Type 2 Diabetes Inadequately Controlled With Prior Metformin Monotherapy
We'll reach out to this number within 24 hrs